EMPAGLIFLOZIN IS ASSOCIATED WITH A LOWER RISK OF POST-ACUTE HEART FAILURE RE-HOSPITALIZATION AND MORTALITY: INSIGHTS FROM THE EMPA-REG OUTCOME TRIAL

Patients admitted for heart failure (HF) are at a high risk for re-hospitalization. Hospital readmissions drive the majority of HF-related costs and in the United States, performance measures tied to reimbursement now focus on reducing early readmissions. The aim of this analysis was to investigate